The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Open accessAbstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PPMS (10-15% of patients) is characterised by an insidious, slowly progressive increase in neurological disability over time, usually without relapses.2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At this time it is considered essential that a diagnosis of MS only be made in a patient who has symptoms suggestive of demyelination. 2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Misdiagnosis of MS remains an issue in clinical practice. 8-11”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationJacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,485
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, Ó., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,042
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 677
Self-citationIncidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009) · Neurology · doi:10.1212/01.wnl.0000335764.14513.1a · Cited by 642
Self-citation
Cited by
Sorted by citations
Items 601–700 of 1,007
Proteomics in Multiple Sclerosis: The Perspective of the Clinician
Sandi, D., Kokas, Z., Biernacki, T., Bencsik, K., Klivènyi, P., & Vécsei, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095162 · Cited by 38
Reeve, K. A., Ön, B. I., Havla, J. B., Burns, J., Gosteli, M., Alabsawi, A., Alayash, Z., Götschi, A., Seibold, H., Mansmann, U., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013606.pub2 · Cited by 37
Grunwald, C., Krętowska-Grunwald, A., Adamska-Patruno, E., Kochanowicz, J., Kułakowska, A., & Chorąży, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052589 · Cited by 39
Understanding multiple sclerosis as a disease spectrum: above and below the clinical threshold
Krieger, S. C., Cook, K., & Hersh, C. M. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001262 · Cited by 39
Portaccio, E., Betti, M., Meo, E. D., Addazio, I., Pastò, L., Razzolini, L., Totaro, R., Spitaleri, D. L. A., Lugaresi, A., Cocco, E. E., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12448-4 · Cited by 38
Self-citationTowards a Unified Set of Diagnostic Criteria for Multiple Sclerosis
Brownlee, W. J., Vidal‐Jordana, Á., Shatila, M., Strijbis, E. M. M., Schoof, L., Killestein, J., Barkhof, F., Bollo, L., Rovira, À., Sastre‐Garriga, J., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27145 · Cited by 39
Self-citationLongitudinal Testing of Olfactory and Gustatory Function in Patients with Multiple Sclerosis
Uecker, F. C., Olze, H., Kunte, H., Christian, G., Göktas, Ö., Harms, L., & Schmidt, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170492 · Cited by 36
Gerhard, L., Dorstyn, D., Murphy, G., & Roberts, R. (2018) · Journal of Health Psychology · doi:10.1177/1359105318755262 · Cited by 36
Murgia, F., Lorefice, L., Poddighe, S., Fenu, G., Secci, M. A., Marrosu, M. G., Cocco, E. E., & Atzori, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030863 · Cited by 36
Ohlmeier, C., Gothe, H., Haas, J., Osowski, U., Weinhold, C., Blauwitz, S., Schmedt, N., Galetzka, W., Berkemeier, F., Tackenberg, B., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231846 · Cited by 36
Diagnosis and management of multiple sclerosis: MRI in clinical practice
Tomassini, V., Sinclair, A., Sawlani, V., Overell, J. R., Pearson, O. R., Hall, J., & Guadagno, J. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09930-0 · Cited by 40
Deciphering Multiple Sclerosis Progression
Meca‐Lallana, V., Ruiz, L. B., Polo, J. C., Eichau-Madueño, S., Ferrer-Lozano, J., Forero, L., Higueras, Y., Lara, N. T., Vidal‐Jordana, Á., & Miralles, F. C. P. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.608491 · Cited by 38
Berek, K., Bsteh, G., Auer, M., Pauli, F. D., Zinganell, A., Berger, T., Deisenhammer, F., & Hegen, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675307 · Cited by 36
Mohammadinasr, M., Montazersaheb, S., Molavi, O., Kahroba, H., Talebi, M., Ayromlou, H., & Hejazi, M. S. (2023) · NeuroMolecular Medicine · doi:10.1007/s12017-023-08744-3 · Cited by 36
Ntranos, A., & LUBLIN, F. D. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0688-8 · Cited by 38
Self-citationImmunophenotypic characterization of CSF B cells in virus-associated neuroinflammatory diseases
Enose‐Akahata, Y., Azodi, S., Smith, B., Billioux, B. J., Vellucci, A., Ngouth, N., Tanaka, Y., Ohayon, J. M., Cortese, I. C. M., Nath, A., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007042 · Cited by 36
Lin, J.-P., Brake, A., Donadieu, M., Lee, A., Smith, G., Hu, K., Nair, G., Kawaguchi, R., Sati, P., Geschwind, D. H., et al. (2025) · Science · doi:10.1126/science.adp6325 · Cited by 35
Microglia in the context of multiple sclerosis
Zhang, X., Chen, F., Sun, M., Wu, N., Liu, B., Yi, X., Ge, R., & Fan, X. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1157287 · Cited by 36
Global Assessment of Palliative Care Need: Serious Health-Related Suffering Measurement Methodology
Kwete, X. J., Bhadelia, A., Arreola‐Ornelas, H., Mendez, O., Rosa, W. E., Connor, S. R., Downing, J. D., Jamison, D. T. T., Watkins, D., Calderón, R., et al. (2024) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2024.03.027 · Cited by 36
Wen, J., Antoniades, M., Yang, Z., Hwang, G., Skampardoni, I., Wang, R., & Davatzikos, C. A. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.04.017 · Cited by 38
Contraceptive use among women with multiple sclerosis: a systematic review
Zapata, L. B., Oduyebo, T., Whiteman, M. K., Houtchens, M. K., Marchbanks, P. A., & Curtis, K. M. (2016) · Contraception · doi:10.1016/j.contraception.2016.07.013 · Cited by 35
iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles
Biasi, S. D., Simone, A. M., Nasi, M., Bianchini, E., Ferraro, D., Vitetta, F., Gibellini, L., Pinti, M., Giovane, C. D., Sola, P., et al. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00555 · Cited by 35
Bakirtzis, C., Ioannidis, P., Messinis, L., Nasios, G., Konstantinopoulou, E., Papathanasopoulos, P., & Grigoriadis, N. (2018) · The Open Neurology Journal · doi:10.2174/1874205x01812010031 · Cited by 35
Calandri, E., Graziano, F., Borghi, M., & Bonino, S. (2018) · Disability and health journal · doi:10.1016/j.dhjo.2018.07.008 · Cited by 37
Kalatha, T., Arnaoutoglou, M., Koukoulidis, T., Hatzifilippou, E., Bouras, E., Balogiannis, S., & Koutsouraki, E. (2019) · Journal of International Medical Research · doi:10.1177/0300060519840550 · Cited by 35
Recent Advances in Smart Biomaterials for the Detection and Treatment of Autoimmune Diseases
Shodeinde, A. B., Murphy, A. C., Oldenkamp, H. F., Potdar, A. S., Ludolph, C. M., & Peppas, N. A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909556 · Cited by 36
The window of opportunity for treatment of progressive multiple sclerosis
Sørensen, P. S., Fox, R. J., & Comi, G. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000811 · Cited by 35
Self-citationOcrelizumab for multiple sclerosis
Lin, M., Zhang, J., Zhang, Y., Luo, J., & Shi, S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013247.pub2 · Cited by 38
Breaching Brain Barriers: B Cell Migration in Multiple Sclerosis
Rodriguez-Mogeda, C., Rodríguez‐Lorenzo, S., Attia, J. V. D., van Horssen, J., Witte, M. E., & de Vries, H. E. (2022) · Biomolecules · doi:10.3390/biom12060800 · Cited by 36
Garis, G., Haupts, M. R., Duning, T., & Hildebrandt, H. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06385-1 · Cited by 35
Tonev, D. G., & Momchilova, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417223 · Cited by 34
Ionescu, R.-B., Nicaise, A. M., Reisz, J. A., Williams, E. C., Prasad, P., Willis, C. M., Simões-Abade, M. B. C., Sbarro, L., Dzieciatkowska, M., Stephenson, D., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.09.014 · Cited by 34
Hart, P. H., Lucas, R. M., Booth, D. R., Carroll, W. M., Nolan, D. A., Cole, J. M., Jones, A. P., & Kermode, A. G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00003 · Cited by 34
Netrin‐1 and multiple sclerosis: a new biomarker for neuroinflammation?
Mulero, P., Córdova, C., Hernández, M., Martín, R., Gutiérrez, B., Muñoz, J. C., Redondo, N., Gallardo, I., Téllez, N., & Nieto, M. L. (2017) · European Journal of Neurology · doi:10.1111/ene.13340 · Cited by 34
Alemtuzumab for the treatment of multiple sclerosis
Evan, J. R., Bozkurt, S. B., Thomas, N. C., & Bagnato, F. R. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1425388 · Cited by 34
Aberrant expression of alternative splicing variants in multiple sclerosis – A systematic review
Hecker, M., Rüge, A., Putscher, E., Boxberger, N., Rommer, P. S., Fitzner, B., & Zettl, U. K. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.05.010 · Cited by 36
Progressive Multiple Sclerosis
Ontaneda, D. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000727 · Cited by 41
CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders
Perdaens, O., Dang, H. A., D’Auria, L., & Pesch, V. V. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000673 · Cited by 34
Burggraaff, J., Liu, Y. Z., Prieto, J. C., Simoes, J., de Sitter, A., Ruggieri, S., Brouwer, I., Lissenberg-Witte, B. I., Rocca, M. A., Valsasina, P., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102549 · Cited by 34
Self-citationMaciak, K., Pietrasik, S., Dziedzic, A., Redlicka, J., Saluk, J., Bijak, M., Wlodarczyk, T. W., & Miller, E. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168946 · Cited by 35
Zveik, O., Fainstein, N., Rechtman, A., Haham, N., Ganz, T., Lavon, I., Brill, L., & Vaknin‐Dembinsky, A. (2022) · Glia · doi:10.1002/glia.24165 · Cited by 35
Aznar, M. D. G., Guerrero, M. D. V., Ramos, J., Madueño, S. E., Bravo, M. M., Ruiz, R. L., & García, M. B. (2022) · BMC Neurology · doi:10.1186/s12883-022-02913-w · Cited by 34
Iron in multiple sclerosis – Neuropathology, immunology, and real-world considerations
Zierfuss, B., Wang, Z., Jackson, A. N., Moezzi, D., & Yong, V. W. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104934 · Cited by 34
Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
Wiendl, H., & Meuth, S. G. (2015) · Drugs · doi:10.1007/s40265-015-0411-0 · Cited by 34
Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields
Cabezas, M., Corral, J. F., Oliver, A., Díez, Y., Tintoré, M., Auger, C., Montalbán, X., Lladó, X., Pareto, D., & Rovira, À. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4829 · Cited by 33
Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis
Bianchini, E., Biasi, S. D., Simone, A. M., Ferraro, D., Sola, P., Cossarizza, A., & Pinti, M. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.01.009 · Cited by 33
Staging of cortical and deep grey matter functional connectivity changes in multiple sclerosis
Meijer, K. A., Eijlers, A. J. C., Geurts, J. J. G., & Schoonheim, M. M. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316329 · Cited by 33
Hvid, L. G., Feys, P., Baert, I., Kalron, A., & Dalgas, U. (2020) · Neurorehabilitation and neural repair · doi:10.1177/1545968320907074 · Cited by 33
The emerging role of lncRNAs in multiple sclerosis
Ghaderian, S., Shomali, N., Behravesh, S., Danbaran, G. R., Hemmatzadeh, M., Aslani, S., Jadidi‐Niaragh, F., Hosseinzadeh, R., Torkamandi, S., & Mohammadi, H. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577347 · Cited by 33
Fransen, N. L., de Jong, B. A., Heß, K., Kuhlmann, T., Vincenten, M. C. J., Hamann, J., Huitinga, I., & Smolders, J. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000955 · Cited by 33
The Impact of SARS-CoV-2 Infection on the Development of Neurodegeneration in Multiple Sclerosis
Dziedzic, A., Saluk, J., Miller, E. D., Niemcewicz, M., & Bijak, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041804 · Cited by 33
van der Walt, A., Butzkueven, H., Shin, R. K., Midaglia, L. S., Capezzuto, L., Lindemann, M., Davies, G., Butler, L. M., Costantino, C., & Montalbán, X. (2021) · Brain Sciences · doi:10.3390/brainsci11091247 · Cited by 34
Laboratory biomarkers of Multiple Sclerosis (MS)
Arneth, B. M., & Kraus, J. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.10.004 · Cited by 34
Treatment of Multiple Sclerosis
Cross, A., & Riley, C. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001170 · Cited by 37
Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide
Wijmeersch, B. V., Hartung, H., Vermersch, P., Pugliatti, M., Pozzilli, C., Grigoriadis, N., Alkhawajah, M. M., Airas, L. M., Linker, R. A., & Oreja‐Guevara, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991291 · Cited by 38
Self-citationThe role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis
Lycke, J., & Zetterberg, H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1400380 · Cited by 33
Plasma exchange in severe acute relapses of multiple sclerosis – Results from a Portuguese cohort
Correia, I., Jesus‐Ribeiro, J., Isidoro, L., Batista, S., Nunes, C. C., Macário, C., Borges, C., Tomaz, J., & Sousa, L. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.12.001 · Cited by 33
Diffusion basis spectrum imaging provides insights into MS pathology
Sun, P., George, A., Perantie, D. C., Trinkaus, K. M., Ye, Z., Naismith, R. T., Song, S., & Cross, A. H. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000655 · Cited by 33
Intermediate uveitis and multiple sclerosis: to scan or not to scan: Table 1
Petrushkin, H., Kidd, D. P., & Pavesio, C. E. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307269 · Cited by 33
Socioeconomic disparity is associated with faster retinal neurodegeneration in multiple sclerosis
Vasileiou, E. S., Filippatou, A. G., Pimentel Maldonado, D., Kalaitzidis, G., Ehrhardt, H., Lambe, J., Saidha, S., Sotirchos, E. S., Mowry, E. M., Calabresi, P. A., et al. (2021) · Brain · doi:10.1093/brain/awab342 · Cited by 32
Self-citationJin, L., Zhang, J., Hua, X., Xu, X., Li, J., Wang, J., Wang, M., Liu, H., Qiu, H., Chen, M., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05202-z · Cited by 33
Disability and Fatigue Can Be Objectively Measured in Multiple Sclerosis
Motta, C., Palermo, E., Studer, V., Germanotta, M., Germani, G., Centonze, D., Cappa, P., Rossi, S., & Rossi, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148997 · Cited by 32
Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
D’Amico, E., Leone, C., Caserta, C., & Patti, F. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1058162 · Cited by 32
Freedman, M. S., Montalbán, X., Miller, A., Dive‐Pouletty, C., Hass, S., Thangavelu, K., & Leist, T. P. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.10.010 · Cited by 32
Self-citationIncidence of multiple sclerosis in the Republic of Ireland: A prospective population-based study
O’Connell, K., Tubridy, N. J., Hutchinson, M., & McGuigan, C. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.02.010 · Cited by 32
Serum Glutamate Is a Predictor for the Diagnosis of Multiple Sclerosis
Gawwam, G. A., & Sharquie, I. K. (2017) · The Scientific World JOURNAL · doi:10.1155/2017/9320802 · Cited by 32
Motor Imagery as a Function of Disease Severity in Multiple Sclerosis: An fMRI Study
Tacchino, A., Saiote, C., Brichetto, G., Bommarito, G., Roccatagliata, L., Cordano, C., Battaglia, M. A., Mancardi, G., & Inglese, M. (2018) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00628 · Cited by 32
Self-citationBeadnall, H. N., Wang, C., Hecke, W. V., Ribbens, A., Billiet, T., & Barnett, M. H. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418823462 · Cited by 32
Hundehege, P., Cerina, M., Eichler, S., Thomas, C., Herrmann, A. M., Göbel, K., Müntefering, T., Fernández‐Orth, J., Böck, S., Narayanan, V., et al. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.259622 · Cited by 32
Diagnosis and Management of Secondary-Progressive Multiple Sclerosis: Time for Change
Oh, J., Alikhani, K., Bruno, T. R., Devonshire, V. A., Giacomini, P. S., Giuliani, F., Nakhai-Pour, H. R., Schecter, R., & Larochelle, C. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2019-0024 · Cited by 34
Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis
Zahoor, I., & Giri, S. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08796-4 · Cited by 37
Iaffaldano, P., Lucisano, G., Patti, F., Morra, V. B., Luca, G. D., Lugaresi, A., Zaffaroni, M., Inglese, M., Salemi, G., Cocco, E. E., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520974366 · Cited by 32
Self-citationBelvisi, D., Canevelli, M., Baione, V., Buscarinu, M. C., Pellicciari, G., Fantozzi, R., Creta, A., Cecchi, G., Cola, G., Nicoletti, C. G., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/1352458520987541 · Cited by 32
Mina, Y., Azodi, S., Dubuche, T., Andrada, F. C., Osuorah, I., Ohayon, J. M., Cortese, I. C. M., Wu, T., Johnson, K. R., Reich, D. S., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102680 · Cited by 35
Potential Biomarkers Associated with Multiple Sclerosis Pathology
Mathur, D., Mishra, B. K., Rout, S., Lopez-Iranzo, F. J., López‐Rodas, G., Vallamkondu, J., Kandimalla, R. J. L., & Casanova, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910323 · Cited by 32
Pietrasik, S., Dziedzic, A., Miller, E. D., Starosta, M., & Saluk, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111887 · Cited by 32
The need for a strategic therapeutic approach: multiple sclerosis in check
Inojosa, H., Proschmann, U., Akgün, K., & Ziemssen, T. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211063032 · Cited by 35
Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis
Williams, T. E., Holdsworth, K. P., Nicholas, J. M., Eshaghi, A., Katsanouli, T., Wellington, H., Heslegrave, A., Zetterberg, H., Frost, C. D., & Chataway, J. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001130 · Cited by 32
Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination
Castillo-Rodriguez, M. D. L. A., Gingele, S., Schröder, L., Möllenkamp, T. M., Stangel, M., Skripuletz, T., & Gudi, V. (2022) · Histochemistry and Cell Biology · doi:10.1007/s00418-022-02096-y · Cited by 33
Qureshi, F., Hu, W., Loh, L., Patel, H., DeGuzman, M., Becich, M. J., da Costa, F. R., Gehman, V. M., Zhang, F., Foley, J. F., et al. (2023) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.202200018 · Cited by 32
Chisari, C. G., Bianco, A. D., Morra, V. B., Calabrese, M., Capone, F., Cavalla, P., Chiavazza, C., Comi, C., Danni, M. C., Filippi, M., et al. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01415-y · Cited by 36
Hammer, L. A., Waldner, H., Zagon, I. S., & McLaughlin, P. J. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215596384 · Cited by 32
New insights into immune reconstitution inflammatory syndrome of the central nervous system
Johnson, T. P., & Nath, A. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000107 · Cited by 32
Whole brain and grey matter volume of Japanese patients with multiple sclerosis
Akaishi, T., Nakashima, I., Mugikura, S., Aoki, M., & Fujihara, K. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.03.009 · Cited by 32
Ayuso, T., Aznar, P., Soriano, L., Olaskoaga, A., Roldán, M., Otaño, M., Ajuria-Morentin, I., Soriano, G., Lacruz, F., & Mendióroz, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174726 · Cited by 32
Burman, J., Киргизов, К. И., Carlson, K. E., Badoglio, M., Mancardi, G., Luca, G. D., Casanova, B., Ouyang, J., Bembeeva, R. T., Haas, J., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.40 · Cited by 32
Characterization of naïve, memory and effector T cells in progressive multiple sclerosis
Nielsen, B. R., Ratzer, R. L., Börnsen, L. S., von Essen, M. R., Christensen, J. R., & Sellebjerg, F. T. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.06.001 · Cited by 32
Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction
Carotenuto, A., Cocozza, S., Quarantelli, M., Arcara, G., Lanzillo, R., Morra, V. B., Cerillo, I., Tedeschi, E., Orefice, G., Bambini, V., et al. (2018) · Brain and Language · doi:10.1016/j.bandl.2018.08.003 · Cited by 32
dos Santos, N. B., Novaes, L. S., Dragunas, G., Rodrigues, J. R., Brandão, W. N., Camarini, R., Peron, J. P. S., & Munhoz, C. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-43217-3 · Cited by 32
Wiendl, H., Elger, C. E., Förstl, H., Hartung, H., Oertel, W. H., Reichmann, H., & Schwab, S. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0348-8 · Cited by 32
Prevalence of multiple sclerosis in key cities of Brazil: a study in Passo Fundo, Southern Brazil
dos Passos, G. R., Becker, J., Varela, D., Fröhlich, A. C., Rech, B. C., de Mattos, A. C. M. T., Callegaro, D., & Lana–Peixoto, M. A. (2021) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2020-0221 · Cited by 31
Speech deficits in multiple sclerosis: a narrative review of the existing literature
Plotas, P., Nanousi, V., Kantanis, A., Tsiamaki, E., Papadopoulos, A. A., Tsapara, A., Glyka, A., Mani, E., Roumelioti, F., Strataki, G., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01230-3 · Cited by 34
The prevalence of insomnia in multiple sclerosis: A meta-analysis
Zeng, X., Dorstyn, D., Edwards, G., & Kneebone, I. (2023) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2023.101842 · Cited by 32
Astrogliosis in multiple sclerosis and neuro-inflammation: what role for the notch pathway?
Mora, P., & Chapouly, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254586 · Cited by 35
Hands on Alemtuzumab-experience from clinical practice: whom and how to treat
Hassoun, L., Eisele, J., Thomas, K., & Ziemssen, T. (2016) · Multiple Sclerosis and Demyelinating Disorders · doi:10.1186/s40893-016-0011-1 · Cited by 31
Guerrero-García, J. D. J., Rojas-Mayorquín, A. E., Valle, Y., Padilla‐Gutiérrez, J. R., Castañeda-Moreno, V. A., Mireles-Ramírez, M. A., Muñóz-Valle, J. F., & Ortuño‐Sahagún, D. (2017) · Immunobiology · doi:10.1016/j.imbio.2017.10.001 · Cited by 31
Silva, B. A., Leal, M. C., Farías, M. I., Ávalos, J. C., Besada, C. H., Pitossi, F. J., & Ferrari, C. C. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.01.010 · Cited by 31
A case for gender-based approach to multiple sclerosis therapeutics
Houtchens, M. K., & Bove, R. M. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.07.001 · Cited by 33
Bagnato, F. R., Franco, G., Ye, F., Fan, R., Commiskey, P., Smith, S. A., Xu, J., & Dortch, R. D. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519833018 · Cited by 31
Adipokines are associated with pediatric multiple sclerosis risk and course
Keyhanian, K., Saxena, S., Gombolay, G. Y., Healy, B. C., Misra, M., & Chitnis, T. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101384 · Cited by 31
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., Kieseier, B. C., Lincoln, J. A., Lubetzki, C., Miller, A. E., Montalban, X., O'Connor, P. W., Petkau, J., Pozzilli, C., Rudick, R. A., Sormani, M. P., Stüve, O., Waubant, E., & Polman, C. H.
- Affiliations
- Cleveland Clinic (US)
- From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet...
- Corresponding author
- Lublin, Fred D.
- ORCID
- Lublin, Fred D.
- Reingold, Stephen C.
- Cohen, Jeffrey A.
- Cutter, Gary R.
- Sørensen, Per Soelberg
- Thompson, Alan J.
- Wolinsky, Jerry S.
- Balcer, Laura J.
- Banwell, Brenda
- Barkhof, Frederik
- Bebo, Bruce
- Calabresi, Peter A.
- Comi, Giancarlo
- Fox, Robert J.
- Goodman, Andrew D.
- Inglese, Matilde
- Kappos, Ludwig
- Lincoln, John A.
- Lubetzki, Catherine
- Miller, Aaron E.
- O'Connor, Paul W.
- Pozzilli, Carlo
- Rudick, Richard A.
- Sormani, Maria Pia
- Stüve, Olaf
- Waubant, Emmanuelle
- Polman, Chris H.
- Venue
- Neurology
- Published
- 2014-07-15
- Volume
- 83
- Issue
- 3
- Pages
- 278-286
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4117366
- OpenAlex
- W2105206040
- Cited by
- 3,177
- References
- 32
- Citations by year
- 2026: 229 · 2025: 266 · 2024: 335 · 2023: 308 · 2022: 333 · 2021: 333 · 2020: 298 · 2019: 274 · 2018: 232 · 2017: 236 · 2016: 193 · 2015: 105 · 2014: 27
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Multiple Sclerosis Society
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Cleveland Clinic
- Novartis Pharmaceuticals Corporation
- University of Alabama at Birmingham
- European Committee for Treatment and Research in Multiple Sclerosis
- Wellcome Trust
- Ironwood Pharmaceuticals, Incorporated
- University of Alabama
- Myelin Repair Foundation
- University of Texas Health Science Center at Houston
- GW Pharmaceuticals
- Acorda Therapeutics
- Prothena
- Glenmark Pharmaceuticals
- National Institute for Health and Care Research
- Multiple Sclerosis Society
- University of Cambridge
- European Commission
- Bayer HealthCare
- Wolfson Foundation
- National Research Foundation
- Eisai
- Multiple Sclerosis International Federation
- Schweizerische Multiple Sklerose Gesellschaft
- Sun Pharma
- Serono Symposia International Foundation
- Grifols
- National Institutes of Health
- Genentech
- EMD Serono
- Bayer Canada
- Sanofi Genzyme
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, clinical course, disease phenotypes, clinical trial design, relapse rate, disease activity, disease progression, MRI findings, biomarkers
- MeSH terms
- Clinical Trials as Topic, Humans, Multiple Sclerosis, Societies, Medical, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
